TruScreen Preliminary Final Results

Results announcement




Results for announcement to the market
Name of issuer Truscreen Group Limited
Reporting Period 12 months to 31 March 2026
Previous Reporting Period 12 months to 31 March 2025
Currency NZ Dollars
Amount (000s) Percentage change
Revenue from continuing
operations
2,434 +42%
Total Revenue 2,829 +34%
Net profit/(loss) from
continuing operations
(2,253) -0.4%
Total net profit/(loss) (2,253) -0.4%
Interim/Final Dividend
Amount per Quoted Equity
Security
N/A
Imputed amount per Quoted
Equity Security
N/A
Record Date N/A
Dividend Payment Date N/A
Current period Prior comparable period
Net tangible assets per
Quoted Equity Security
$0.003 $0.002
A brief explanation of any of
the figures above necessary
to enable the figures to be
understood
See attached announcement
Authority for this announcement
Name of person

authorised
to make this announcement
Guy Robertson Chief Financial Officer
Contact person for this
announcement
Guy Robertson
Contact phone number +61 407 983 270
Contact email address guyrobertson@truscreen.com
Date of release through MAP

29 May 2026

Unaudited financial statements accompany this announcement.

---

NZX/ASX Announcement
29 May 2026
TruScreen FY2026 Preliminary Results
(all numbers in NZ dollars)

Cervical cancer technology company Truscreen Group Limited (NZX/ASX: TRU) (the Company) has today
released its preliminary unaudited financial results for the financial year ended 31 March 2026.

Highlights include:

• Launch of 5-year programme to screen 260,000 women for cervical cancer in Ho Chi Minh City, Vietnam
• TruScreen re-enters the Indian market and appoints Renovate Biologicals Pvt Ltd to distribute its AI
enabled TruScreen cervical cancer screening system in India
• Landmark publication of the multi year and multi province clinical trial by Germany’s BMC Cancer.
Notable publications including Sichuan University clinical study, and the Guilin People’s Hospital study,
confirm TruScreen’s superiority as a primary screening medical device, and a superior screening choice
for pregnant women
• TruScreen submitted three proposals to UNITAID's Global Cervical Cancer Elimination Call to Action,
covering 14 high burden countries and an addressable screening market of 1Bn women.
• Growing TruScreen’s distribution network with appointment of new distributors in South Africa and
Uzbekistan, with pending appointments in Nigeria, Romania, Bangladesh and Sri Lanka
Financial year 31 March 2026 was a year of marketing growth and consolidation for TruScreen.

Truscreen achieved product sales growth of 42% YOY to FY2026, and the sales were achieved from a broader
range of participant countries. This included first sales in India with 468 million
1
screening-age women and
Indonesia with 95 million
2
of screening age and a government funded mass screening program, creating
enormous growth opportunity.

TruScreen is accelerating new market development, with a diversified geographic distribution footprint that will
provide leverage to improve commercial returns. TruScreen’s additional drive to participate in public screening
programmes requires investment, but achieving scale and meeting clinical need will shorten the pathway to
profitability.

TruScreen has recently submitted three proposals to UNITAID for cervical cancer screening programmes across
14 high-burden countries in Africa, Asia-Pacific, and Latin America – addressable market 1Bn women, with
potential revenue as a consortium lead for TruScreen of up to US$18.4 million. TruScreen’s point-of-care portable
AI technology is purpose-built for the settings where cervical cancer kills most, where there are no laboratories,
no pathologists, and no patient recall second visit.

1
*CIA World Factbook women aged 15-64 = 467,593,7814
2
*CIA World Factbook women aged 15-64 = 95,961,293

TruScreen enables primary screening where labs are absent, HPV triage where HPV (including Dalton Bio) is
primary, and same-visit complement in screen-and-treat settings. This creates a complementary rather than
competitive relationship with HPV expansion.

Gross margin in FY2026 was 31.5% (2025: 30.1%). Gross margin is expected to further improve in FY2027 with
revenue from a broader range of countries. Other income was in line with the prior year at $0.4m (2025: $0.4m).

Total overhead expenses were $3.4m (2025: $3.1m) reflecting additional marketing and support costs as the
Company strives to broaden its revenue base. The result for the year was a loss of $2.25m (2025: $2.24m) with
the additional margin on revenue being offset by additional costs incurred as the Company grew its distributor
base and focus on large public screening programmes in collaboration with global NGO’s working with countries
to meet WHO’s 90-70-90 milestones by 2030.



TruScreen in FY2026 expanded its reach into a number of new countries. A brief summary of development by country
is as follows:


China
• China remained our largest market, accounting for 61.3% of total sales. Despite challenging economic
conditions, consumable sales volume met expectations.
• Landmark clinical study results from the Chinese Obstetricians and Gynaecologists Association (COGA) were
published in the leading German journal BMC Cancer and Springer Nature Link in February 2026. This largest-
ever study of opto-electronic cervical screening further validated TruScreen as a superior primary cervical
cancer screening tool.
29
FY25 ACTUALFY26 ACTUAL
NZ$1.7m
Unaudited sales NZ$2.4m

Vietnam
• TruScreen was successfully adopted by four leading public hospitals in South Vietnam, establishing a
foundation for broader hospital acceptance.
• TruScreen has entered the growing private health sector. One hospital has integrated TruScreen into its daily
clinic operations, while four additional clinics are awaiting government approval for installation and three more
are preparing their application documentation for submission.
Indonesia
• The pilot clinical study is currently underway. Results will be presented by the lead investigator at the Annual
Scientific Meeting of POGI (the Indonesian Obstetrics and Gynaecology Association) in July 2026. TruScreen
and distributor Marwa Mitra Medika are sponsoring the conference and will conduct a symposium to launch
TruScreen in Indonesia.
• Leveraging the pilot clinical study results, Marwa Mitra Medika will collaborate with the Ministry of Health to
include TruScreen in government public screening programs.
India
• New distributor Renovate Biological was appointed in April 2025.
• Interim Product Testing license was obtained in July 2025, permitting Renovate Biological to import up to 10
TruScreen devices, which have been shipped, for clinical study and training purposes. A consortium of private
hospitals will adopt TruScreen subject to regulatory approval.
• Application for regulatory approval was submitted in April 2026, with approval expected within 3 to 6 months.
Singapore, Malaysia and Thailand
• Product registration with Singapore's HSA was obtained in September 2025.
• Product registration with Thailand's FDA was obtained in April 2026.
• Product registration in Malaysia was submitted in March 2026, with approval expected shortly.
• A reference centre for S E Asia has been established in Singapore with local Key Opinion Leader, Dr. S. C.
Quek at the Parkway Gynaecology Screening & Treatment Centre, Gleneagles Hospital.
Bangladesh
• New distributor Xerox Medica Limited was appointed in May 2026, with potential first-year sales in FY2027.
• Government procurement application to be submitted in June 2026 to meet government budget deadline.
Mexico
• Distributor Sunbird launched social media and digital marketing campaigns, established online training and
information centres for TruScreen. It generated significant interest, and is building a strong sales pipeline.
• TruScreen has entered the laboratory system where large volumes of cervical cancer screenings are conducted.
Sunbird is in discussions to collaborate with major laboratory chains. Sales are expected to commence in
FY2027.
Uzbekistan
• New distributor appointed in May 2026. Albatros Health Care LLC is a leading medical device distributor in the
country. The potential sales revenue for the 30-month period through calendar year 2028 is over NZD 1 million.

• Led by a senior government medical advisor, and with ethics approval, the pilot Clinical study will commence in
June 2026.
Central Asia
• Distributor IMSystem is conducting a multi-centre clinical study to meet requirements for TruScreen to be
recognized as a primary screening method in all government healthcare providers and screening programs.
Two centres have begun screening 1,500 women, with two additional centres commencing in May 2026 to
screen the remaining 500 women.
• Kazakhstan will commence commercial use of TruScreen in early FY2027. Product registrations have been
submitted in Kyrgyzstan and Belarus, with approvals expected in Q3 FY2027.
Zimbabwe
• The re-validation study was completed by the National Microbiology Reference Laboratory in August 2025. The
positive results enabled the Ministry of Health to approve TruScreen as a primary screening test for locations
where HPV DNA testing is unavailable and as a confirmatory test for HPV-positive women nationwide. This is
an expansion from the previous single-province deployment.
• Following re-validation, the screening program resumed with a planned 20,000 screenings in calendar year
2026.
South Africa
• New distributor AIR was appointed in November 2025.
• Product registration with the South African Health Products Regulatory Authority (SAHPRA) was submitted in
March 2026, with approval expected in July 2026.
• A pilot clinical study to support market entry has been planned to commence when regulatory approval is
received.
Nigeria
• TruScreen collaborated with Nigeria's Lagos State University Teaching Hospital (LASUTH) and Lagos State
University College of Medicine (LASUCOM) on a Bill & Melinda Gates Foundation grant application. Dr.
Ayokunle Moses Olumodeji, Consultant Gynaecological Oncologist at LASUTH, selected TruScreen's AI-
enabled cervical cancer screening medical device as the cornerstone of his proposed study to validate
TruScreen's integration into existing clinical settings.
• The first clinical reference centre in Africa will be established in Nigeria with Professor Chibuike Chigbu at
University of Nigeria Teaching Hospital.
• Collaborative relationships have been developed with local NGOs including Solina Centre for International
Development and Research (SCIDaR) and RedAid.

Other new distributors appointed include Romania and Italy. We are in final discussions with potential distributors in
Nigeria, Rwanda, Sri Lanka, and Palestine.

Corporate

The Company raised approximately $4 million during the year, with the issue of approximately 190.7 million shares at
$0.022 per share. These funds have enabled the Company to expand its geographic reach and engage in new initiatives
which have strengthened the foundation for improved financial performance in FY2027.

Attached to these shares is one free attaching option, exercisable at $0.022, which term has been extended to 17 July
2027.

Ms Juliet Hull retired as a director at the annual shareholders meeting on 11 September and Ms Christine Pears was
elected by shareholders as a director. She has over 20 years’ experience as Chair, independent director and executive
of both listed and private companies.

Our CEO, Martin Dillon, as foreshadowed in an announcement in February 2026, will rejoin the Company on 1 June
2026 and will be key in TruScreen’s drive for transformational growth.

Mr Chris Horn, as advised in early April 2026 will retire shortly after thirteen years as a director of the Company. The
Company is currently seeking to appoint an Australian based Non-executive director.


Authorised by the Board for filing with the NZX/ASX.



For more information, visit www.truscreen.com or contact:
Tony Ho
Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com
Jack Zhang
Media & Investor Relations
jack@sparkplus.org

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures
an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low
level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and processing of
biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel
and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for cervical cancer screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA
(Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico).
It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has
distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices
marketed and sold in China.
TruScreen technology is recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical Pathology) China
Cervical Cancer Screening Management Guidelines and the COGA Blue Book.
In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical
List, for use in Vietnam’s public and private healthcare sectors and in 2024 was added to the Russian guidelines
for the screening of cervical cancer.
In financial year 2025 alone, over 200,000* examinations were performed with the TruScreen device. To date,
over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi
Arabia. TruScreen’s vision is “A world without the cervical cancer”.
To learn more, please visit: www.truscreen.com/.
*Based on Single Use Sensor sales.

About DaltonBio:

DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on in vitro
diagnosis (IVD) in women's health and oncology. DALTONbio is the leader in human papillomavirus (HPV)
nucleic acid testing and comprehensive cervical cancer detection and screening. Its HPV DNA detection kits
(DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture
technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This
technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening. DALTONbio’s
exceptional, clinically proven products have saved tens of millions of lives in the world. They have aided health
professionals in detecting, diagnosing, and treating illnesses earlier and more effectively, resulting in healthier
people everywhere, every day.

To learn more, please visit: www.daltonbio.com/.

---

TRUSCREEN GROUP LIMITED





Preliminary Final Report
Consolidated Financial Statements - Unaudited

Currency is New Zealand Dollars

For the Year Ended 31 March 2026


Contents
Consolidated Summary of Profit or Loss and Other
Comprehensive Income
2
Consolidated Statement of Financial Position 3
Consolidated Statement of Changes in Equity 4
Consolidated Statement of Cash Flows 5
Notes to the Financial Statements 6

TRUSCREEN GROUP LIMITED
The accompanying notes form part of these financial statements.
2
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2026
Note 2026 2025
$

$
Revenue from the sale of goods
3
2,434,476

1,712,052
Other income
3
394,534

393,203



Product cost of goods sold

(1,666,675) (1,196,832)
Employee benefit expenses and directors’ fees

(705,496)

(856,761)
Other administration costs

(537,090) (501,808)
Research and development expenses

(929,401)

(814,614)
Rent

-

(12,550)
Travel

(101,501) (74,402)
Marketing and product approvals

(710,847)

(627,860)
Insurance

(142,608)

(140,162)
Shareholder relations and services

(236,730) (107,064)
Share based payments

(36,829) -
Borrowing cost

(14,575) (16,678)
Loss before income tax

(2,252,742) (2,243,476)
Income tax expense

- -
Loss for the year

(2,252,742) (2,243,476)
Other comprehensive income


Item that may be reclassified subsequently to
profit or loss


Exchange differences on translating foreign
subsidiary operations


169,531 (46,268)


169,531
(46,268)
Total comprehensive loss for the year

(2,083,211)

(2,289,744)



Basic and diluted loss per share (cents)
4
(0.032) (0.41)

TRUSCREEN GROUP LIMITED
The accompanying notes form part of these financial statements.
3
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2026
Note 2026 2025
$ $
CURRENT ASSETS
Cash and cash equivalents 1,462,603 365,473
Other receivables 396,916 411,012
Trade receivables 1,026,962 22,798
Inventories 451,943 538,679
Other current assets – prepayments 225,064 203,544
TOTAL CURRENT ASSETS 3,563,488 1,541,506
NON-CURRENT ASSETS
Intangible assets - -
Right of use assets 185,377 306,851
TOTAL NON-CURRENT ASSETS 185,377 306,851
TOTAL ASSETS 3,748,865 1,848,357

CURRENT LIABILITIES
Trade and other payables 813,211 387,317
Lease liability 159,112 133,211
Provision for employee benefits 109,511 104,096
TOTAL CURRENT LIABILITIES 1,081,834 624,624
NON-CURRENT LIABILITIES
Provision for employee benefits 39,986 31,190
Lease liability 41,583 184,161
TOTAL NON-CURRENT LIABILITIES 81,569 215,351
TOTAL LIABILITIES 1,163,403 839,975
NET ASSETS 2,585,462 1,008,382

EQUITY
Issued capital 5 42,432,428 38,772,137
Share option reserve 41,374 89,643
Foreign currency translation reserve (213,865) (383,396)
Accumulated losses (39,674,476) (37,470,002)
TOTAL EQUITY 2,585,462 1,008,382

TRUSCREEN GROUP LIMITED
The accompanying notes form part of these financial statements.
4

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2026


Note
Share
Capital
Accumulated
Losses
Foreign
Currency
Translation
Reserve
Option
Reserve

Total

$

$
$ $
$



Balance at 1 April 2025
38,772,137 (37,470,002)
(383,396)
89,643 1,008,382
Loss for the year to 31 March
2026

- (2,252,742) - - (2,252,742)
Exchange differences on
translating foreign subsidiary
operations


- - 169,531 - 169,531
Total comprehensive income for
the year

- (2,252,742) 169,531 - (2,083,211)
Transactions with owners, in their capacity as owners


Issue of shares

4,048,018 -
-

-
4,048,018
Share issue costs

(387,727) -
-

-
(387,727)
Share based payments

- 48,269
-
(48,269) -
Total transactions with owners
3,660,291 48,269
-

(48,269)
3,660,291
Balance at 31 March 2026
42,432,428 (39,674,476)
(213,865)
41,374 2,585,462


Note
Share
Capital
Accumulated
Losses
Foreign
Currency
Translation
Reserve
Option
Reserve

Total

$

$
$ $
$



Balance at 1 April 2024
38,705,945 (35,371,339)
(337,128)
234,456 3,231,934
Loss for the year to 31 March
2024

- (2,243,476) - - (2,243,476)
Exchange differences on
translating foreign subsidiary
operations


- - (46,268) - (46,268)
Total comprehensive income for
the year

- (2,243,476) (46,268) - (2,289,744)
Transactions with owners, in their capacity as owners


Issue of shares

66,192 -
-
- 66,192
Share issue costs

- -
-

-
-
Share based payments

- 144,813
-

(144,813)
-
Total transactions with owners
66,192 144,813
-

(144,813)
66,192
Balance at 31 March 2025
38,772,137 (37,470,002)
(383,396)
89,643 1,008,382

TRUSCREEN GROUP LIMITED
The accompanying notes form part of these financial statements.
5
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 MARCH 2026

Note 2026 2025

$

$
CASH FLOW FROM OPERATING ACTIVITIES

Cash received from customers
1,472,115 1,716,718
Cash paid to suppliers and employees including GST (4,429,805) (4,416,220)
Cash received from research and development tax
offset

482,719 447,140
Short-term lease payments not included in lease
liability

- (38,490)
Interest paid (2,009) (3,296)
Interest received 6,213 4,842
Net cash used in operating activities (2,470,767) (2,289,306)

CASH FLOW TO INVESTING ACTIVITIES
Purchase of plant and equipment - -
Net cash used in investing activities - -

CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from issue of shares 3,989,671 -
Share issue costs (375,268) -
Principal element of lease payments (121,057) (84,398)
Net cash from financing activities 3,493,346 (84,398)

Net increase/(decrease) in cash and cash
equivalents

1,022,580 (2,373,704)
Cash and cash equivalents at the beginning of the
financial year

365,473 2,728,036
Effects of exchange rate changes on cash and cash
equivalents

74,550 11,141
Cash and cash equivalents at the end of the
financial year


1,462,603 365,473

6
NOTE 1. MATERIAL ACCOUNTING POLICY INFORMATION
General Information
These preliminary final unaudited consolidated financial statements and notes represent those of Truscreen
Group Limited and its subsidiaries (the “Group”). References to “Truscreen” is used to refer to Truscreen
Group Limited (the “Company”).
The parent company, Truscreen Group Limited, is the ultimate legal parent company of the Group and is a
limited liability company incorporated and domiciled in New Zealand. It is registered under the Companies
Act 1993. Truscreen is listed on the NZX and on the ASX as an ASX Foreign Exempt Listing.
Truscreen
is a FMC reporting entity under Part 7 of the Financial Markets Conduct Act 2013.
The registered office of the Company is Level 6 Equitable House, 57 Symonds St, Grafton, Auckland 1010,
New Zealand. The Group is engaged in the business of the development, manufacture and sale of cancer
detection devices and systems.
Basis of Preparation
These preliminary final financial statements have been prepared under the historical costs convention,
modified by the revaluation of certain assets and liabilities as identified in specific accounting policies
below.
The principal accounting policies adopted in the preparation of the financial report are set out below. These
policies have been consistently applied to all the periods presented, unless otherwise stated.
The financial statements have been rounded to the nearest dollar.
Going Concern
The Group preliminary final unaudited financial statements have been prepared on a going concern basis,
which contemplates the continuity of normal business activity and the realisation of assets and the
settlement of liabilities in the normal course of business.
As disclosed in the financial statements, the Group reports;
• a loss of $2,252,742 (2025: $2,243,476).
• net cash outflows from operating and investing activities of $2,470,766 (2025: $2,289,306)
• cash at year-end of $1,462,603 (2025: $365,473)
The Company undertook a capital raise in May 2026 raising approximately $1.82 million in a share
placement and with further funds expected in a Renounceable Rights issue to be completed on the 17 June
2026.
The Directors have undertaken a detailed cash flow forecast for the twelve months following the date of
approval of this report, which shows that the business will be able to meet its debts as and when they fall
due, for at least the next twelve months. The forecasts assume revenue growth from a number of markets,
and takes into account current expectations of device and SUS orders from key distributors.
The Company also continues to review and reduce its cost base where appropriate.
The Board considers the cash flow forecasts to be achievable and sufficient to provide cash to cover any
operating deficit and capital expenditure. The Board consider managing cash flow and working capital
critical in successfully executing the strategies to achieve the business model of the Group. However, there
is material uncertainty in relation to the Group’s ability to meet forecasts. These factors may cast significant
doubt on the entity’s ability to continue as a going concern.
If the going concern assumption is not valid, the consequence is the Group may be unable to realise the
value in its assets and discharge its liabilities in the normal course of business.

7
NOTE 2. SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS
The Company makes estimates and assumptions concerning the future that affects the amounts reported in
the financial statements. Estimates and judgments are continually evaluated and based on historical
experience and other factors, including expectations of future events that are believed to be reasonable
under the circumstances. The estimates will, by definition, seldom equal the related actual results. The
estimates and assumptions that have a significant risk of causing material adjustments to the carrying
amounts of assets and liabilities within the next financial year are discussed below:
• Going Concern
Refer to note 1.
• Revenue from Contracts with Customers
The application of NZ IFRS 15: Revenue from contracts with customers (NZ IFRS 15) requires the
Directors to apply judgement in determining whether revenue can be recognised in advance of the receipt
of cash.

The significant judgements adopted by the Group in applying NZ IFRS 15 criteria include:
• Determining if a contract with the customer exists;
• Determining if the entity can identify the payment terms for the services; and
• Determining whether it is probable that the entity will collect the consideration to which it is entitled.
• Intangibles
The carrying value of intangibles include acquired intellectual property and development costs capitalised
in accordance with the accounting policy for research and development.
The intangibles were fully written off in a previous year.
Given the ongoing significant uncertainty associated with achieving revenue and profitability targets, the
Directors have determined that the intangibles should remain fully impaired as at 31 March 2026.
• Recognition of deferred taxation assets
The benefit of deferred tax arising from tax losses and temporary differences has not been recognised.
• Estimate of the Research and Development tax offset
The Group receives a research and development tax offset based on 43.5% of research and development
expenditure incurred. The amount is received following filing of the Group income tax returns. The Group
estimates the amount of the offset assisted by external consultants and accounts for the amount as a
receivable at year end.
• Provision for inventory obsolescence
The Group carries inventory of parts for the manufacture of the TruScreen Ultra® cervical cancer screening
device. The Company will write off parts which it no longer considers usable. The Group has made a
general provision for inventory obsolescence.
• Provision for warranty
The Group will undertake recalibration of the TruScreen Ultra® on an ongoing basis during the warranty
period. While the Group will continue to undertake research and development of the product, the TruScreen
Ultra® is a mature and well tested product and the Group has determined on the basis of materiality that no
warranty provision is necessary.
• Share based payments
The Group measures the cost of equity-settled transactions with directors, employees and distributors by
reference to the fair value of the equity instruments at the date at which they are granted. The fair value is
determined using a Black-Scholes model.

8


NOTE 3. REVENUE




2026 2025

$ $
Sales revenue - sale of goods¹


Wholesalers/distributors

1,902,752 1,712,052
Direct to customer

531,724 -


2,434,476 1,712,052
Other income


Research and development tax offset


- Current year

303,550 383,236
- Prior year adjustment

85,799 (20,885)


389,349 362,351
Foreign exchange gain

- 26,297
Interest received

5,185 4,555


394,534 393,203
¹Ownership of goods transfers to the distributor/customer on leaving Truscreen’s premises or that of the
outsourced manufacturer when shipped directly to customers.
NOTE 4. EARNINGS PER SHARE




2026 2025
Basic and Diluted loss per share:
Net loss attributable to shareholders ($) (2,252,742) (2,243,476)
Weighted average number of ordinary shares on issue 700,894,546 552,743,441
Basic and diluted loss per share (cents) (based on
weighted average number of shares on issue) (0.32) (0.41)

NOTE 5. ISSUED CAPITAL

a) Ordinary Shares – Fully Paid


2026 2026 2025 2025
Group
Number $ Number $
Balance at beginning of the year 554,907,719 38,772,137 552,591,116 38,705,945
Share issue - advisor - - 2,316,603 66,192
Shares issued for services rendered 1,701,576 35,702 - -
Share purchase plan @ NZ$0.02 per share 83,681,940 1,673,639 - -
Share placement @ NZ$0.022 per share 107,034,091 2,354,750 - -
Foreign exchange adjustment on A$ raise - (16,073) - -
Cost of capital raising - (387,727) - -
Balance at end of the year 747,325,326 42,432,428 554,907,719 38,772,137

9


NOTE 5. ISSUED CAPITAL (Continued)

No particular number of shares are authorised. There is no par value of shares.
All issued ordinary shares carry equal rights in respect of voting and the receipt of dividends, and upon
winding up rank equally with regard to the Company’s residual assets.
b) Options
The Company issued 204,741,031 unlisted options on 17 July 2025. The options were free attaching
options to the share placement and share purchase plan announced on 29 May 2025.
The options have an exercise price of NZ$0.022 (A$0.02) and an expiry date of 17 July 2026. The expiry
date of these options has now been extended to 17 July 2027.

NOTE 6. CASH FLOW INFORMATION 2026 2025
$ $
Reconciliation of cash flow from operations with loss
after income tax


Loss for the period (2,252,742) (2,243,476)
Adjusted for:


Share based payment expense 36,829 -
Depreciation right of use assets 140,065 102,061
Unrealised exchange difference arising from
translating loss

49,715 (8,894)
Operating cash flows before working capital changes
(2,026,133)
(2,150,309)
(Increase)/decrease in trade and other receivables (1,004,163) 25,354
Increase in goods and services taxes recoverable (50,454) (2,182)
Increase in prepayments
(21,521)
(85,941)
Decrease/increase in inventory 86,737 (47,425)
Decrease in research and development tax offset 64,550 80,506
Increase/(decrease) in trade and other payables
466,006
(99,880)
Increase/(decrease) in employee liabilities 14,211 (9,429)
Net cash outflow from operating activities
(2,470,767)
(2,289,306)

---

Highlights FY2026
Outlook for FY2027
May 2026

Who is TruScreen
Enabled by AI, TruScreen provides
an accurate, real time cervical
cancer screening solution

3
TruScreen Group Ltd is a revenue generating Life Science
company with a unique, AI-enabled real-time cervical cancer
screening device.
FY26 annual sales exceeded NZD $2.4m
- 42% YOY growth.
TruScreen Group Ltd owns TruScreen
Pty Ltd, the Australian operating
company that manufactures and
markets the TruScreen cervical cancer
screening system.

4
2025 & BeyondBuilding for the Future 2020-2024
Building the Fundamentals 2014 - 2020
The TruScreen Journey
2025
China Growth continues
Distribution of Dalton Bio IVD HPV DNA products
Vietnam HPHA program targets 260,000 women
Indonesia and ASEAN commence commercial use
Distributor appointed in South Africa
Global focus on AI boosts recognition of TruScreen
2018 Oct
523% sales
growth in H1
2019 May
Recognition by
World Health
Organization
2020 Jan
ASX Listing
2014 Nov
Listing on NZAX
2023-24
COGA Blue Book and CSCCP Guidelines include
TruScreen
UNITAID recognises TruScreen’s value for Cervical
Cancer screening
WHO invited TruScreen to participate in Key AI
meeting for cervical cancer screening
Vietnam – HPHA large scale screening MOU signed
2018 Jul
Comm ence large
scale pilo t
programs in China
with CDC and COG
2018 Dec
Migration to NZX
2022
Managing COVID-19 challenges
Cost reduction
Manufacturing and business
development in China
Completion of major COGA study
Strengthen distributor arrangement in
Vietnam
2017 Dec
CFDA (NMPA)
approval for second
generation device
2026
Uzbekistan and Zimbabwe screening
programs to commence
UNITAID and Gates Foundation
funding applications made
Distributor appointed in Romania
Landmark COGA paper published

TruScreen
Sales Strategy

6
Device installations and SUS Sales
KEY FINANCIALS
NZD (m)
FY 23
Actual
FY 24
Actual
FY25
Actual
FY26 Actual
(unaudited)
Sales1.662.11.72.4
Total Revenue2.22.62.12.8
COGS1.31.41.21.7
R&D0.90.90.80.9
EBITDA-2.4-2.0-2.2-2.2
Write off of Non-Current
Assets
-0.05---
Amortisation &
Depreciation
----
LOSS FOR YEAR-2.4-2.0-2.2-2.2
Net Assets2.53.21.02.6
Cash2.22.70.041.5
From FY25 to FY26:
⚫Sales increased 42% YOY
⚫SUS Sales increased 1% YOY
⚫Revenue increased 33% YOY
⚫EBITDA – no change YOY
⚫Net Assets increased 160% YOY
⚫China SUS/Device Pull Through -4% YOY

7
FY25 ACTUALFY26 ACTUAL
NZ$1.7m
Unaudited sales NZ$2.4m

8
Recurring Revenue Model
•TruScreen manufactures two devices –
oone made in China for use in China, where locally manufactured products
have preferential market access
oone made in Australia for other markets
•For each patient screened with the TruScreen device a new disposable Single
Use Sensor (SUS) must be used. This creates a recurring revenue model with a
consumable sale for each patient screened with TruScreen.

9
TruScreen Sales Strategy
•Whilst many other medical technology companies seek to commercialize their devices
in developed countries, TruScreen focuses on Low and Middle Income Countries (LMICs)
such as China, Mexico, Vietnam, India, Indonesi and Zimbabwe.
•Working with global and national NGOs, to manage large scale public health screening
programs
•These countries and other LMICs have no or minimal large-scale cervical cancer
screening programs and infrastructure. This creates a gap in the market for TruScreen
that is not available in the developed markets and allows quicker market access from a
relative lack of existing competition.
•In comparison with cytology and HPV DNA screening TruScreen is ‘capital light’, not
requiring lab infrastructure to be established prior to commencing screening.

10
•World Health Organisation (WHO)
•UNITAID
•Clinton Health Access Initiative
•Daffodil Foundation - Australia
•China Obstetricians and
Gynaecologists Association
•China Society for Colposcopy and
Cervical Pathology
•Russia Cervical Cancer Screening
Guideline
•Vietnam Hospital Technical List
•CE Mark, European Union
•NMPA, China
•TGA, Australia
•MHRA, UK
•SFDA, Saudi Arabia
•Roszdravnadzor, Russia
•COFEPRIS, Mexico
•WAND New Zealand
•Zimbabwe Ministry of Health
•IEAKI Indonesia
•Vietnam MOH
•India (Test Licence)
•Uzbekistan
•HSA, Singapore
•Thai FDA
TruScreen Regulatory Approvals
•ISO 13485
•IEC 60601-1
•IEC 60601-1-2
•CE Mark
International Approvals:Recognized by
International Quality
Accreditation:

11
Saudi Arabia study published with
sensitivity 83.3% and specificity 95%
compared with Pap test of 66.7% and
98.2% respectively
Uzbekistan product registration completed to enable the
validation trial of TruScreen for a national cervical cancer
screening program
COFEPRIS approval for
use in Mexico Public
Health system
Launch of 5 year, 260,000 women
cervical cancer screening program
at Ho Chi Minh City Public Health
Association
Indonesian distributor appointed
with commercial sales
commenced in a significant
addressable market
Inclusion in Chinese Obstetricians and
Gynecologists Association (COGA) Blue
Book guideline and China Society for
Colposcopy and Cervical Pathology
(CSCCP) guideline
India distributor
appointed (world’s
second most
populous country)
Revalidation completed
for additional public
screening programs in
Zimbabwe
Appraisal by Baylor
Foundation from the
US for a public
screening program in
Eswatini
Global presence
Registration and Sales activity in Russia, Kazakhstan,
Kyrgyzstan, Armenia and Belarus
Europe CE mark held as proof of
quality and efficacy
Product registration granted in
Singapore and Thailand, and
Malaysia is underway
Distributor appointed
in South Africa and
product registration
underway
Rwanda
distributor to be appointed
Romania
distributor appointed
Nigeria distributor
to be appointed
Bangladesh
distributor
appointed

TruScreen Highlights
FY 2026

13
FY2026 Highlights — Five Marquee Wins
01
260,000-woman Vietnam programme
5-year cervical cancer screening programme
launched in Ho Chi Minh City with HPHA & Gorton
Health Services. Planned national expansion in a
market of 35M women of screening age.
02
India re-entry
Renovate Biologicals Pvt Ltd appointed as
distributor. Interim product testing licence (Jul-
25), 10 devices shipped. Full regulatory
submission Apr-26.
03
BMC Cancer landmark study
14,982 women, 64 hospitals, 9 provinces. CIN2+
sensitivity 87%, CIN3+ sensitivity 90%. Largest
opto-electronic cervical screening study ever
published.
04
UNITAID — 3 proposals submitted
14 high-burden countries, 1Bn women
addressable market, up to US$18.4m potential
revenue as consortium lead.
05
Distributor footprint expanded
New distributors signed in South Africa,
Uzbekistan, Bangladesh, Romania and Italy.
Pending in Nigeria, Rwanda and Palestine.

14
A Diversified Global Footprint
Active markets
■China (61.3% of FY26 sales)
■Vietnam (4 public hospitals + private)
■Zimbabwe (national expansion)
■Mexico (lab-system entry)
■Central Asia / Russia (multi-centre)
Launching FY27
■India (regulatory approval pending)
■Indonesia (POGI launch · July 2026)
■Singapore · Thailand · Malaysia
■Bangladesh (Xerox Medica)
■Kazakhstan (commercial use early FY27)
Pipeline / new signings
■South Africa (AIR · pilot study)
■Uzbekistan (Albatros Health Care)
■Romania · Italy (signed)
■Nigeria (LASUTH · Gates Foundation
app.)
■Rwanda · Sri Lanka · Palestine (in
negotiations)

15
China — The Anchor Market
61.3%
of FY2026 product sales
Consumable sales volumes met expectations despite
challenging economic conditions.
Anticipated guideline integration into:
■CSCCP guidelines update
■COGA Blue Book — 2nd edition (2026)
■Expert Consensus on opto-electronic screening
Landmark BMC Cancer publication · Feb 2026
14,982
women
64
hospitals
9
provinces
Clinical performance vs Liquid-Based Cytology & hrHPV
87%
CIN2+ sensitivity
90%
CIN3+ sensitivity
0.72
AUC for CIN2+
"TruScreen has the highest AUC for both CIN2+ and CIN3+, indicating it was the
most accurate test overall." — Study authors, BMC Cancer (2026)

16
Vietnam & Indonesia — South-East Asia Growth Engine
Vietnam
260,000
women to be screened in Ho Chi Minh City over 5 years (with HPHA & Gorton
Health Services)
■Adopted by 4 leading public hospitals in South Vietnam.
■Private-sector entry: 1 hospital integrated into daily clinic; 4 awaiting
approval; 3 more preparing applications.
■Planned national expansion — Vietnam has ~35M women of screening
age.
■Foundation for broader public-sector hospital acceptance now
established.
Indonesia
95M
women of screening age — government-funded mass screening program
creates enormous opportunity
■Pilot clinical study underway with Marwa Mitra Medika.
■Results to be presented at POGI Annual Scientific Meeting — July
2026.
■TruScreen & distributor sponsoring the conference and product
launch symposium.
■Collaboration planned with Ministry of Health for inclusion in public
screening programmes.

17
India Re-Entry & South-East Asia Regulatory Progress
India
468M
women of screening age
Renovate Biologicals Pvt Ltd appointed distributor (Apr-25). Interim product testing licence (Jul-25) — 10 devices
shipped. Regulatory submission filed Apr-26, approval expected within 3-6 months. Consortium of private
hospitals lined up to adopt TruScreen subject to approval.
Regulatory & market-entry milestones — South-East Asia
IndiaSouth-East Asia
Apr 2025
Renovate Biologicals
appointed (India)
Jul 2025
Interim product
testing licence (India)
Sep 2025
Singapore HSA
registration obtained
Mar 2026
Malaysia registration
submitted
Apr 2026
Thailand FDA
registration obtained
Apr 2026
India regulatory
submission filed
SE Asia reference centre established with Dr. S. C. Quek at Parkway Gynaecology Screening & Treatment Centre, Gleneagles Hospital, Singapore.

18
Africa — Three Growth Stories
Zimbabwe
20,000
screenings planned in CY2026
Re-validation by the National Microbiology
Reference Lab (Aug-25) led the Ministry of Health
to approve TruScreen as a primary screening test
where HPV DNA testing is unavailable, and as a
confirmatory test for HPV-positive women
nationwide. 30,000+ women already screened
since 2022 with the National AIDS Council.
South Africa
Jul 26
SAHPRA approval expected
New distributor AIR appointed (Nov-25). Product
registration with the South African Health
Products Regulatory Authority submitted Mar-26.
A pilot clinical study has been planned to
commence on receipt of regulatory approval,
supporting market entry.
Nigeria
Gates
Foundation grant application
Collaboration with LASUTH and LASUCOM on a
Bill & Melinda Gates Foundation grant application,
TruScreen selected as the cornerstone device.
First African clinical reference centre to be
established with Prof. Chibuike Chigbu, University
of Nigeria Teaching Hospital. NGO partnerships
with SCIDaR and RedAid.

19
Central Asia, LatAm & New Distributors
Uzbekistan
NZD 1.26m
30-mo revenue potential through
CY2028
Albatros Health Care LLC appointed (May-26) a
leading medical device distributor. Pilot clinical
study commencing June 2026 with ethics
approval, led by a senior government medical
advisor.
Central Asia
2,000
women in multi-centre study
IMSystem multi-centre clinical study to secure
recognition as a primary screening method in
government healthcare. Kazakhstan to
commence commercial use early FY27.
Kyrgyzstan & Belarus registrations expected Q3
FY27.
Mexico
FY27
sales expected to commence
Distributor Sunbird ran social media and digital
campaigns and established online training
centres. Now entering the laboratory system
and in discussions with major laboratory
chains.
Bangladesh
NZD 554k
projected first-year sales
New distributor Xerox Medica Limited
appointed (May-26). Government procurement
application to be submitted June 2026 to meet
the budget deadline.

20
UNITAID — A Step-Change Opportunity
14
high-burden countries
across Africa, Asia-Pacific & LatAm
1Bn
addressable screening-age
women across target geographies
US$18.4m
potential revenue to TruScreen
as consortium lead
Why TruScreen fits the UNITAID brief
■Point-of-care, portable AI technology — purpose-built for low-resource settings where laboratories, pathologists and patient recall are unavailable.
■Primary screening where labs are absent · HPV triage where HPV (incl. Dalton Bio) is primary · same-visit complement in screen-and-treat settings.
■Complementary, not competitive, to HPV-DNA expansion under the WHO 90-70-90 elimination strategy.
Track record: 30,000+ women already screened in Zimbabwe since 2022 with the National AIDS Council · regulatory
approvals across all 14 target countries.

21
Clinical & Scientific Milestones
Jan 2025
WHO AI Collaboration
TruScreen invited to present at WHO Global AI
Collaboration Meeting on cervical cancer screening.
May 2025
Saudi Arabia study
Published Saudi Arabia study confirms TruScreen
sensitivity and specificity vs. pap smear.
Jan 2026
Pregnancy safety
Clinical study validates TruScreen efficacy and safety
for pregnant women — broadens use cases.
Feb 2026
BMC Cancer landmark
World’s largest opto-electronic study — 14,982
women, 64 hospitals. CIN2+ 87%, CIN3+ 90%, AUC
0.72.
Mar 2026
Sichuan University
297-patient study shows TruScreen + hr-HPV co-
testing is superior to either modality alone.
Through 2026
30+ trials cumulative
TruScreen now backed by 30+ peer-reviewed studies
covering 40,000+ women across 20+ countries.

22
Commercial & Distributor Expansion
Asia-Pacific
Jan 2025
Indonesia distributor appointed (95M women).
Apr 2025
India re-entry — Renovate Biologicals Pvt Ltd.
Apr 2025
Vietnam — 260,000-woman public programme
launches in HCMC.
May 2025
Dalton Bio HPV distribution rights for India.
Aug 2025
Public screening — Northeast India.
May 2026
Uzbekistan distributor formally appointed.
Africa & Middle East
Nov 2025
South Africa — AIR Group appointed as distributor.
Mar 2026
South Africa — SAHPRA registration submission filed.
May 2026
Nigeria — LASUTH / Gates Foundation grant
submitted.
Dec 2025
Western Europe & Middle East commercial scoping.
Pipeline & Studies
Feb 2025
MOU with Hangzhou Dalton Bioscience.
Aug 2025
Public screening programme — Uzbekistan.
2026
New distributors signed in Romania and Italy.
2026
Pending in Rwanda, Sri Lanka, Palestine, Bangladesh.

TruScreen Outlook:
FY2027 & Growth
Strategies

24
What’s Coming Next
FY2027 outlook
India
Full regulatory approval expected within 3–6
months of Apr-26 filing.
South Africa
SAHPRA approval expected Jul 2026; pilot study to
follow.
Indonesia
Commercial use targeted in FY27.
Uzbekistan
Scale-up under new distributor + public
programme.
UNITAID
Funding decisions on three proposals through
CY2026.
Margin
Country mix expected to lift gross margin above
FY26’s 31.5%.
Catalyst Drivers
H2 CY2026
India regulatory approval; first commercial shipments.
H2 CY2026
South Africa SAHPRA approval and pilot study start.
H2 CY2026
UNITAID consortium decisions.
H2 CY2026
Indonesia / ME market activation.
CY2026
Nigeria — first African clinical reference centre opens.
CY2027
Vietnam — national expansion beyond HCMC.

25
Growth Strategies
Market expansion to continue with China the key focus
Focus on key growth provinces (Shandong, Jiangsu,, Hunan, Zhejiang, Guangdong, Guangxi) - Total
population 496m
Enter huge African market collaborating with NGOs
Strengthen vertical Asian market from Indonesia through China, and capitalise on Indian
distribution network
Target Govt and NGO funded programs in Zimbabwe, Vietnam, Mexico and Uzbekistan

26
Reduce SUS and Device COGS and increase margins
Focus on countries with limited or nil cervical screening capability
Developing strategic partnerships for complementary woman’s health services
Capitalise on global focus on AI enabled cervical cancer technologies – e.g. WHO
Expand product portfolio to include Dalton Bio HPV related IVD products, including HPV DNA tests
and self sampling
Build on International NGO Recognition (WHO, UNITAID, CHAI, COGA , CSCCP) to build acceptance
and remove barriers to sale

27
The Game Changer
The timeline compression of WHO’s
90-70-90 milestones
1
to December
2030 - Sense of Urgency
UNITAID and global NGOs
funding by late 2026 to drive
cervical cancer screening
1
2
1
https://www.who.int/initiatives/cervical-cancer-elimination-initiative

28
TruScreen Market Potential

29
DaltonBio Strategic Alliance
1.TruScreen to be appointed a global distributor of DaltonBio HPV related IVD products (excluding U.S.A. and Canada).
2.DaltonBio to explore opportunities to assist sales of TruScreen’s AI enabled real time cervical screening device within its
distribution network, notably in its selected distributors in China and South America. DaltonBio have 200 sub distributors in
China which may augment TruScreen’s current distribution network in it’s largest market.
•Q4 FY25 - Memorandum of Understanding signed with Dalton
Biosciences (DaltonBio)
•Q1 FY26 - TruScreen and Dalton Bio sign Distribution Agreement for HPV
products in India
The collaboration will enhance access to innovative cervical cancer screening and detection solutions by leveraging the
technology strengths of both companies. As demonstrated in the COGA landmark study (2023) and Beijing Obstetrics and
Gynecology Hospital study (Dovepress, May 2025), co-testing improved TruScreen’s already impressive standalone sensitivity
significantly.

Thank you.
Guy Robertson
Chief Financial Officer
E – guyrobertson@truscreen.com
Tony Ho
Executive Chairman
E – tonyho@truscreen.com
TruScreen
Suite 3.03 18 Orion Rd
Lane Cove West NSW 2066
Australia
www.truscreen.com

31
Disclaimer
This presentation has been prepared by TruScreen Group Limited (the “Company”) and is dated 25 August 2023. This presentation contains summary information about the Company and its
activities which is current as at the date of this presentation. The information in this presentation is of a general nature and does not purport to be complete nor does it contain all the information
which a pros pective investor may require in evaluating a possible investment in the Company. This presentation should be read in conjunction with the Company’s annual report, market releases
and other periodic and continuous disclosure announcements, which are available at www.nzx.com. This presentation does not constitute an offer, advertisement or invitation in any place in which,
or to any person to whom, it would not be lawful to make such an offer, advertisement or invitation.
Not financial product advice
This presentation is for information purpos es only and is not financial or investment advice or a recommendation to acquire the Company’s securities, and has been prepared without taking into
account the objectives, financial situation or needs of pros pective investors. Before making an investment decision, pros pective investors should consider the appropriateness of the information
having regard to their own objectives, financial situation and needs and consult a financial adviser, solicitor, accountant or other professional adviser if necess ary.
Past performance
Any past performance information given in this presentation is given for illustrative purpos es only and should not be relied upon as (and is not) an indication of future performance. No
representations or warranties are made as to the accuracy or completeness of such information.
Future performance
This presentation includes certain “forward-looking statements” about the Company and the environment in which the Company operates. Forward-looking information is inherently uncertain and
subject to contingencies, known and unknown risks and uncertainties and other factors, many of which are outside of the Company’s control, and may involve significant elements of subjective
judgement and assumptions as to future events which may or may not be correct. A number of important factors could caus e actual results or performance to differ materially from any forward-
looking statements. No assurance can be given that actual outcomes or performance will not materially differ from the forward-looking statements. The forward-looking statements are based on
information available to the Company as at the date of this presentation. Except as required by law or regulation (including the Listing Rules), the Company undertakes no obligation to provide any
additional or updated information whether as a result of new information, future events or results or otherwis e.